Skip to content

Feasibility and Preliminary Effect of Baduanjin Program for People Diagnosed With Schizophrenia

Feasibility and Preliminary Effect of Baduanjin Program for People Diagnosed With Schizophrenia: A Pilot Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04027634
Enrollment
22
Registered
2019-07-22
Start date
2014-09-30
Completion date
2014-12-31
Last updated
2019-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Randomized Controlled Trial

Keywords

Baduanjin program, body mass index, metabolic parameters, schizophrenia

Brief summary

Introduction Low levels of physical activity and central obesity contribute to metabolic syndrome in patients with schizophrenia. Aim This study was to examine the effectiveness of Baduanjin program on body mass index (BMI) and five metabolic parameters in participants with chronic schizophrenia. Methods A randomized controlled trial was conducted in a psychiatric center in northern Taiwan. The eligibility criteria included BMI \> 25 kg/m2, or with metabolic syndrome. Twenty-two participants were randomized to two groups using blocked randomization. The experimental group was provided with an 8-session Baduanjin program for 12 weeks (1 h, thrice times per week), while the control group received routine care.

Detailed description

This study was conducted in a large psychiatric center that has 10 residential rehabilitation units. Residents were allowed to walk for 20 min during 6-7 pm every day, and each unit could accommodate approximately 50 residents. In this study, patients on the schizophrenia spectrum were invited to receive screening for metabolic syndrome. A total of 108 patients agreed to undergo the screening, and forty-seven patients were confirmed to have metabolic syndrome. Patients with metabolic syndrome or BMIs \> 25 kg/m2 were invited to participate in the research. In total, sixty-two patients satisfied the inclusion criteria, and 22 patients consented to participate in the experiment. Each participant was assigned one number from 1 to 22 by the first author. The second author enrolled participants. They were randomized to either Baduanjin program group or routine care group in a 1:1 ratio using blocked randomization having a block size of 4 by the fourth author. Patients in the experimental group (EG) participated in the Baduanjin intervention in a privacy setting, which involved 60-min sessions 3 times per week, 1 h after dinner between 6 and 7 pm; the entire program continued for 12 weeks. The control group (CG) received routine care and was required to walk during 6-7 pm. The outcome indicators for this intervention program involved the risk factors for metabolic syndrome, BW, and BMI. When schizophrenia becomes chronic, patients experience lack of motivation. This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program. While these participants practiced the Baduanjin program, the CG participants walked for 15-20 min in their wards.

Interventions

This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.

Sponsors

Taipei Veterans General Hospital, Taiwan
CollaboratorOTHER_GOV
National Yang Ming Chiao Tung University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

The data of the five metabolic indexes, height, and BW were collected by a research assistant.

Intervention model description

The participants were divided into experimental and control groups through block randomization.

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* People were diagnosed with schizophrenia at the age of 20-65 years. * People had taken regular antipsychotic medication for more than 10 weeks * People lacked regular exercise in the past 3 months. * People consented to receive blood collection and complete a questionnaire. * People satisfied the modified Adult Treatment Panel III criteria for Asians i.e., three abnormal results for metabolic syndrome or two abnormal results with BMI \> 25)

Exclusion criteria

* People with organic mental disorders, alcohol dependence, and substance abuse. * people who are not willing to sign the consent.

Design outcomes

Primary

MeasureTime frameDescription
Body weight3 monthsChange from Baseline Body weight (kilograms) at 3 months
body Mass Index (BMI).3 monthsBMI is defined as Body weight(kilograms) divided by height (meter) squared

Secondary

MeasureTime frameDescription
triglyceride3 monthsChange from Baseline triglyceride (mg/dl) at 3 months
Fasting blood sugar3 monthsChange from Baseline Fasting blood sugar (mg/dl) at 3 months
high-density lipoprotein3 monthsChange from Baseline high-density lipoprotein (mg/dl) at 3 months
Blood pressure3 monthsChange from Baseline Blood pressure (mmHg) at 3 months
Waist circumference3 monthsChange from Baseline Waist circumference (inches) at 3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026